{"article": [{"url": "https://www.marketwatch.com/story/johnson-johnsons-stock-inches-up-after-profit-and-sales-beat-raised-outlook-2020-07-16", "published": 1594882880.0, "headline": "Johnson & Johnson's stock inches up after profit and sales beat, raised outlook", "body": "Shares of Johnson & Johnson JNJ, +1.39% rose less than 0.1% in premarket trading Thursday, to buck the selloff in the broader market, after the drug and consumer health products company reported second-quarter profit and sales that beat expectations, and raised its full-year outlook. Net income fell to $3.63 billion, or $1.36 a share, from $5.61 billion, or $2.08 a share, in the year-ago period. Excluding non-recurring items, adjusted EPS fell to $1.67 from $2.58 but beat the FactSet consensus of $1.49. Sales declined 10.8% to $18.34 billion but was above the FactSet consensus of $17.61 billion. Consumer health sales fell 7.0% to miss expectations, while pharmaceutical sales grew 2.1% to slightly top expectations and medical device sales dropped 33.9% but was above expectations. \"Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,\" said Chief Executive Alex Gorsky. The company raised its 2020 guidance ranges for adjusted EPS to $7.75 to $7.95 from $7.50 to $7.90 and for sales to $79.9 billion to $81.4 billion from $77.5 billion to $80.5 billion. J&J's stock gain comes as Dow Jones Industrial Average DJIA, +0.56% futures YM00, +0.82% slumped 151 points, or 0.6%."}]}